• Publications
  • Influence
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition
TLDR
The genomes of uterine and ovarian CSs demonstrated that these different cell types derive from a common precursor cell that has many mutations typical of epithelial cancers, and expression of specific histone gene mutations in uterine carcinoma cells changed gene expression toward a mesenchymal state. Expand
Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
TLDR
In this largest comprehensive study, 35% of endometrial serous carcinoma harbors HER2 protein overexpression and/or gene amplification, over half of which demonstrate significant heterogeneity of protein expression. Expand
Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
TLDR
Taselisib represents a novel therapeutic option in patients harboring PIK3CA mutations and/or HER2/neu gene amplification and dose-dependent decline in the phosphorylation of S6 in the G0/G1 phase of the cell cycle. Expand
Past, present and future targets for immunotherapy in ovarian cancer.
TLDR
The different immunotherapies available for ovarian cancer as well as current ongoing studies and potential future directions are reviewed. Expand
HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies
TLDR
Tyrosine kinase inhibitors and immunotherapy with monoclonal antibodies targeting HER2 hold promise for patients harboring these aggressive neoplasms. Expand
Claudins Overexpression in Ovarian Cancer: Potential Targets for Clostridium Perfringens Enterotoxin (CPE) Based Diagnosis and Therapy
TLDR
These surface proteins may represent attractive targets for the detection and treatment of chemotherapy-resistant ovarian cancer and other aggressive solid tumors overexpressing claudin-3 and -4 using CPE-based theranostic agents. Expand
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
TLDR
Oncogenic PIK3CA mutations are common in HER2/neu-amplified USC and may constitute a major mechanism of resistance to trastuzumab treatment. Expand
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR
TLDR
Oncogenic PIK3CA mutations and c-erbB2 gene amplification may represent biomarkers to identify patients harboring USC who may benefit most from the use of GDC-0980. Expand
Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.
TLDR
This is the largest study of its kind showing a safe, effective and rapid (3.5h) CD protocol and the majority of patients with a history of either carboplatin hypersensitivity reaction or a positive skin test completed the CD protocol without HSRs. Expand
Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
TLDR
Neratinib may be a potential treatment option for patients harboring HER2/neu amplified USC and clinical trials for this subset of endometrial cancer patients are warranted. Expand
...
1
2
3
4
5
...